Drug intelligence / Profile preview

CLL-001

Development stage: Unknown
Lead developer: CELL Technologies
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

CLL-001 (ChondroStem) is an autologous stem cell therapy being developed by CELL Technologies for the treatment of knee osteoarthritis. The therapy utilizes bone marrow aspirate concentrate (BMAC) containing the patient's own bone marrow-derived stem cells, which are processed and delivered at the point of care via intra-articular injection. By avoiding freezing and thawing, CLL-001 maintains high cell viability and functionality, delivering fresh stem cells to promote tissue regeneration, reduce inflammation, and improve joint function. CLL-001 is currently in Phase 3 clinical development.

Brand names: ChondroStem
Other names: BMACBone Marrow Aspirate Concentrateautologous bone marrow aspirate concentrateautologous bone marrow-derived stem cells

Beyond the preview

Go deeper on CLL-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLL-001.

Explore the full profile